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Background: Quantifying population health is important for public health policy. Since national disease registers
recording clinical diagnoses are often not available, pharmacy data were frequently used to identify chronic
conditions (CCs) in populations. However, most approaches mapping prescribed drugs to CCs are outdated and
unambiguous. The aim of this study was to provide an improved and updated mapping approach to the
classification of medications. Furthermore, we aimed to give an overview of the proportions of patients with CCs in
Switzerland using this new mapping approach.
Methods: The database included medical and pharmacy claims data (2011) from patients aged 18 years or older.
Based on prescription drug data and using the Anatomical Therapeutic Chemical (ATC) classification system,
patients with CCs were identified by a medical expert review. Proportions of patients with CCs were calculated by
sex and age groups. We constructed multiple logistic regression models to assess the association between patient
characteristics and having a CC, as well as between risk factors (diabetes, hyperlipidemia) for cardiovascular diseases
(CVD) and CVD as one of the most prevalent CCs.
Results: A total of 22 CCs were identified. In 2011, 62% of the 932′612 subjects enrolled have been prescribed a
drug for the treatment of at least one CC. Rheumatologic conditions, CVD and pain were the most frequent CCs.
29% of the persons had CVD, 10% both CVD and hyperlipidemia, 4% CVD and diabetes, and 2% suffered from all
of the three conditions. The regression model showed that diabetes and hyperlipidemia were strongly associated
with CVD.
Conclusions: Using pharmacy claims data, we developed an updated and improved approach for a feasible and
efficient measure of patients’ chronic disease status. Pharmacy drug data may be a valuable source for measuring
population’s burden of disease, when clinical data are missing. This approach may contribute to health policy
debates about health services sources and risk adjustment modelling.
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The evaluation of the population health status, patients’
health care needs and its associated costs is a priority
issue in health policy, decision-making and resource
allocation debates. In general, data of national disease
registries and prevalence surveys, including clinical diag-
noses according to the International Classification of
Diseases (ICD-10-codes) have regularly been used to
estimate the health status of a population. However,
this type of data pool is not available in all health care
systems. In Switzerland, for example, epidemiological
data, providing information on the prevalence of chronic
diseases and comorbidities in general population, are not
widely available.
Administrative databases such as drug prescription
data have thus been frequently used to identify persons
with chronic conditions, quasi as an indirect method to
estimate prevalence. Pharmacy based claims data provide
a consistently available information source, which is reli-
able, covers a large population and might be extremely
useful for assessment of morbidity [1-6]. Pharmacy-
based diagnosis were used in risk adjustment models
[7-9], illness severity measurement [10,11], prevalence
estimates [12-15] and epidemiological studies for comor-
bidity adjustments [16,17]. However, in these studies the
clustering of the Anatomical Therapeutic Chemical
(ATC)-codes has not been applied consistently, and even
in few studies the used ATCs are not documented.
Moreover, the well-known ATC-algorithm of Lamers/
van Vliet [18-20], the Pharmacy-based Cost Group
(PCG) model, was often used in various modified and
unspecified defined versions. The PCG model distin-
guishes 22 chronic conditions and was primarily devel-
oped to predict cost of diseases for risk adjustment.
However, this model has some limitations. Medication
classifications based on data, which have been recorded
about 10 years ago. New drugs, which had not been de-
veloped and thus were not commercially available in the
past years, were not included in the model. Furthermore,
previous studies claimed the possibility of an exact
differentiation between specific diseases via ATC code
[12,19-21]. For example beta-blockers and diuretics were
assigned to the category “hypertension” [19,22]. How-
ever, beta-blockers were also prescribed in patients with
other cardiovascular diseases. Another example, di-
uretics were included in the category “cardiovascular
diseases” although diuretics were also frequently used in
patients with renal diseases [12,21]. In several medica-
tion classes, an ambiguous assignment of medication to
chronic conditions is challenging and even, in certain
cases, infeasible.
To overcome the limitations of previous mapping
approaches, and to suggest a standardised and transpar-
ent use of the mapped medication classes to chronicconditions, we aimed to develop an updated mapping
algorithm with a special focus on the unambiguous as-
signment of prescription drugs to chronic diseases. We
provide an updated and rather conservative mapping ap-
proach to the classification of medications. Our classifi-
cation is on the one side detailed as possible and on the
other side we summarise categories to the superior cat-
egory of disease when needed. Furthermore, we give an
overview of the proportions of chronically ill patients in
Switzerland using pharmacy data.Methods
Study design and population
This study was a cross-sectional study covering all 26
cantons in Switzerland during the study period of
January 1, 2011 to December 31, 2011. The study sample
included all mandatory insured individuals aged 18 years
or older insured by the Helsana Insurance Group, the
leading Swiss health insurer. Individuals who died during
the calendar year 2011 were also included in our study
sample. In Switzerland, each resident has a mandatory
basic coverage which is financed by a premium. All
Swiss health insurants have an insurance coverage with
cost sharing consisting of co-payments and deductibles.
Co-payments are a charge of 10% of the health care
costs per year which every person has to pay. This co-
payment is limited to 700 Swiss francs (Sfr) per year.
Deductibles range from 300 (Sfr) to a maximum of 2500
(Sfr) per year and can be chosen by the insurants. The
amount of the premium decreases when the patient
choose higher deductibles.Data source
Medical claims data were used from Helsana, covering
about 1.3 million Swiss residents with mandatory health
insurance. Population characteristics comprised gender,
age, regional variables (e.g. language area) and the type
of health insurance plan (managed care model, accident
coverage, type of deductible class). The database also in-
cluded information on health care visits, prescription
drugs and drug costs. Drug data were based on medica-
tions prescribed in the outpatient setting including pre-
scribed drugs which were purchased directly at the
pharmacy. The outpatient setting comprised practice-
based primary care physicians and specialists, as well as
physicians from ambulatories, outpatient clinics and
walk-in clinics. In our database, all prescribed drug items
were coded according to the WHO ATC classification
system [23]. Our (drug) data are highly reliable because
the collected insurance claims covered almost all health
care and pharmacy invoices. Since about 3% of the in-
voices were directly paid by the patient and not submitted
for reimbursement, only a small percentage of invoices
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the study data was provided by the Helsana Group.
Identification of chronic diseases
The Anatomical Therapeutic Chemical (ATC) classifica-
tion system was used to classify drugs and was controlled
by the WHO Collaborating Centre for Drug Statistics
Methodology. Each drug ingredient was assigned to the so
called ATC code and was classified into different groups
according to the human organ system on which they act.
Ingredients can be used in different local application for-
mulations: oral, inhalation, nasal, injection, installation,
parenteral, rectal, transdermal, sublingual/buccal, implant,
vaginal. Based on the WHO-report on ATC classification
system, ATC-codes were assigned to chronic conditions
by a medical expert group consisting of primary and
secondary care physicians as well as health services re-
searchers. We only included ATC-codes for chronic dis-
eases which are exclusively used for the treatment of these
diseases. Some drugs may be assigned to two chronic dis-
eases simultaneously. For example, loop or “high-ceiling”
diuretics (e.g. sulfonamides) are most frequently used in
patients with heart failure but also in patients with poor
renal function (chronic kidney disease). Additionally, beta-
blockers are prescribed both in patients with hypertension
and in patients with other cardiovascular diseases. In
general, an unique assignment of ATC-codes to heart
diseases is challenging. Since new trends in the use of
various drugs for cardiac and hypertensive patients have
been established over the last years, a clear distinction be-
tween ATC-codes for cardiac diseases and for hyperten-
sion is infeasible. Therefore, we conservatively evaluated
the ATCs related to chronic diseases and generated rela-
tively broad ATC-groups (e.g. “cardiovascular diseases
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matched to a certain disease, were excluded. In our data-
base, all ATC-codes referring to these ATC-groups classes
were coded with the correspondingly chronic condition.
Statistical analyses
We calculated the point prevalence of chronic condi-
tions (CC) by dividing the number of patients with
at least one prescribed drug in one of the generated
ATC-groups CC at the end of the given year
(31.12.2011) by the total number of insured persons
aged ≥ 18 years at the end of 2011 (31.12). We pre-
sented proportions of patients with chronic condi-
tions stratified by sex and age.
In this study, we also described the situation of pa-
tients with cardiovascular diseases. Cardiovascular dis-
eases are the leading cause of death and are becoming
an increasing economic and social burden for industrial-
ized societies [24]. Therefore, we calculated prevalence
rates of cardiovascular diseases (including hypertension)
in combination with their risk factors, diabetes and
hyperlipidemia, by age.
Furthermore, we estimated multiple logistic regression
models to determine independent associations between
age, sex, regional variables, the type of health insurance
plan, and the occurrence of any chronic condition.
Additionally, we performed a logistic regression to deter-
mine factors associated with the presence of cardiovas-
cular diseases (including hypertension) as dependent
variable. The independent variables included cardiovas-
cular risk factors such as diabetes and hyperlipidemia, as
well as patient characteristics described in the previous
model. Analyses were performed using the software
package R (version 2.12.2).
Results
Based on prescription drug data, we identified a total of
22 diseases. Table 1 summarises the chronic conditions
with the assigned medication classes.
Table 2 shows the population characteristics of our
study sample. We identified 932′612 adult individuals of
a total of more than 1′300′000 subjects in 2011. There
were slightly more woman (53%) than men. The mean
age of the population was 51 years. About 40% of the
sample chose a health insurance plan with managed care
and 30% a deductible class over 500 Swiss francs.
Approximately two thirds of the sample had one or
more medication classes assigned with chronic condi-
tions. Since several patients have been prescribed more
than one disease related medication, multimorbidity
could be observed. About 45% of the population had at
least two chronic conditions (result not shown).
Within both gender groups, the number of medication
classes assigned to chronic conditions increased linearlywith age, as plotted in Figure 1. The strongest increase
from approximately 1.5 to 3 chronic conditions was ob-
served in patients aged between 40 and 70 years. The
curve was moderately rising in younger (18–40 years) as
well as in older age (>70 years). Female patients were
prescribed slightly more drugs for chronic diseases
compared to male patients. On average, patients suffered
from about two chronic conditions in the age group of
50–59 years, from about three chronic conditions in
the age group of 60–69 years and from slightly more
than three conditions in the age group of over 69 years
or older.
The number and proportions of insured persons in
each ATC-group are presented in Table 3. The largest
proportions of persons suffered from rheumatologic
conditions (36%), cardiovascular diseases including
hypertension (29%), pain (28%) and psychological
disorders including sleep disorders and depressions
(21%). About 20% of the individuals have been pre-
scribed a drug for treating acid related disorders, 12%
for hyperlipidaemia and 7% for respiratory illnesses in-
cluding asthma and COPD.
Figure 1 Mean number of chronic conditions among all patients by sex and age.
Table 3 Number and proportion of patients by chronic condition
Chronic condition Number of patients Proportion of patients (%)
Acid related disorders 183′211 19.6
Bone diseases (osteoporosis) 22′159 23.8
Cancer 13′105 1.4
Cardiovascular diseases (incl. hypertension) 269′993 29.0
Dementia 16′780 1.8
Diabetes mellitus 50′751 5.4
Epilepsy 27′225 2.9
Glaucoma 33′640 3.6
Gout, Hyperuricemia 16′332 1.8
HIV 1′956 0.2
Hyperlipidemia 114′698 12.3
Intestinal inflammatory diseases 4′542 0.5
Iron deficiency anemia 38′022 4.1
Migraines 11′325 1.2
Pain 261′225 28.0
Parkinson’s disease 10′942 1.2
Psycholgical disorders (sleep disorder, depression) 197′490 21.2
Psychoses 30′024 3.2
Respiratory illness (asthma, COPD) 68′595 7.4
Rheumatologic conditions 336′373 36.1
Thyroid disorders 35′053 3.8
Tuberculosis 799 0.1
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hyperlipidemia, 4% CVD and diabetes, and 2% suffered
from all of the three conditions (results not shown). As
showed in Figure 2, the prevalence of cardiovascular
diseases (including hypertension), hyperlipidemia and
diabetes was continuously increasing with age. Fur-
thermore, there was a strong increase in the propor-
tion of patients between 40 and 70 years suffering from
cardiovascular diseases in combination with hyperlip-
idemia and/or diabetes mellitus. For the age group
40–49 years, the prevalence was 2.2% for cardiovascu-
lar diseases combined with hyperlipidemia, 1.1% for
cardiovascular diseases with diabetes and 0.5% for car-
diovascular diseases with hyperlipidemia and diabetes.
For the age group of 70–79 years, the proportion of pa-
tients with cardiovascular diseases combined with
hyperlipidemia was 29.5%, with diabetes 12.4% and
with both hyperlipidemia and diabetes 7.5%. With ex-
ception of cardiovascular diseases, every proportion of
patients with chronic condition and its combinations
slightly decreased in older age groups (70–79 and >79
years). Additional analyses could show that 35% of pa-
tients with cardiovascular diseases were also treated
for hyperlipidemia and 15% for diabetes mellitus.
About 9% of the patients with cardiovascular diseases
were both hypertensive and diabetic (results not
shown).
To identify independent predictors of the occurrence
of any chronic condition, we estimated a multipleFigure 2 Proportions of patients with cardiovascular diseases and thelogistic regression model (Table 4). Female sex and older
age strongly predicted the prevalence of any chronic
condition. We constructed a second multiple logistic
regression to determine risk factors for prevalent cardio-
vascular diseases. Older age and suffering from diabetes
mellitus and hyperlipidemia were independently associ-
ated with prevalent cardiovascular diseases (inclusive
hypertension).
Table 5 gives an overview on our estimated pro-
portions of patients with cardiovascular diseases,
diabetes mellitus, hyperlipidemia, cancer and respira-
tory illness (asthma, COPD) compared to those pro-
portions from available data sources in Switzerland
[25-35]. Proportions of cancer, cardiovascular dis-
eases, diabetes and respiratory illness reported in
previous studies were similar to our estimates using
pharmacy data [25,28,31,34]. However, previous find-
ings about the prevalence of hyperlipidemia were
about twice as high than those estimated in our
pharmacy based study [27,33].
Discussion
This study developed an updated mapping approach to
identify chronically ill patients using pharmacy data.
Databases on prescribed drugs are an useful source of
information on morbidity, if reliable medical diagnoses
are missing.
In our classification model, we identified a total of 22
chronic conditions based on the 2011 WHO-ATC-ir risk factors by age.
Table 4 Risk factors for chronic conditions in multivariate





Variable OR* 95%-CI† OR* 95%-CI†
Gender
Women 1.39 1.38-1.41 0.89 0.88-0.90
Age groups
18-29 1.00 1.00
30-39 1.50 1.48-1.53 2.16 2.07-2.24
40-49 1.65 1.62-1.67 4.20 4.05-4.36
50-59 2.27 2.23-2.31 8.85 8.55-9.16
60-69 3.95 3.89-4.02 17.20 16.62-17.79
70-79 7.79 7.62-7.97 34.44 33.24-35.68
>79 8.73 8.50-8.97 60.80 58.61-63.07
Language area
German 1.00 1.00
French 1.25 1.23-1.26 0.87 0.85-0.88
Italian 1.11 1.09-1.14 0.84 0.82-0.86
Rhaeto-Romanic 0.82 0.74-0.90 0.77 0.67-0.88
Insurance plan
Managed care 1.001 0.99-1.01 0.92 0.91-0.93
Deductible class
(> 500 Swiss francs/year)
0.25 0.25-0.25 0.36 0.35-0.36




Nagelkerke R2 0.28 0.52
*Odds ratio.
†95% confidence interval.
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persons suffered from pain, rheumatologic conditions
and cardiovascular diseases, including hypertension.
These findings are in line with previous studies in Italy
estimating prevalence of chronic diseases showing high-
est rates in cardiovascular diseases and rheumatologic
conditions [12,13]. On the other hand, our results are
different from the Dutch estimates based on the PCG-
model showing a low prevalence rate in rheumatologic
conditions [19]. One explanation is the fact that a differ-
ent and partly out-dated medication classification for the
chronic conditions was used. New drugs, which have
been developed during the last decade, were not in-
cluded in the PCG-model performed in the nineties. We
assume that the Italian results may be more exact, since
a more recent medication classification was used in
comparison to the Dutch study. Several of our estimated
proportions of patients with chronic conditions are com-
parable to prevalence estimates in other Europeancountries. For example, the prevalence of diabetes melli-
tus, as one of the leading health problems in the indus-
trialised countries, is similar to the prevalence in
Germany and the Netherlands [15,36,37]. Additionally,
the prevalence rates of asthma are comparable to those
reported in other European countries such as France,
Norway and Germany [38]. Not surprisingly and in line
with several studies, we could show that chronic condi-
tions affected all ages, but with a significant increase in
older age groups [39-42]. Furthermore, we found that
cardiovascular diseases are mainly attributable to clas-
sical risk factors such as diabetes and hyperlipidemia. A
large body of epidemiological and pathological data also
demonstrated that diabetes and dyslipidemia are inde-
pendent risk factors for cardiovascular diseases in both
men and women. Diabetes and hyperlipidemia are com-
mon comorbidities of cardiovascular diseases and con-
tributed significantly to its overall mortality [43-47].
A further aim of our study was to compare our esti-
mated proportions of chronically ill patients with the
reliable prevalence estimates from national studies.
Therefore, we compared our estimated proportions of
patients with cardiovascular diseases, diabetes mellitus,
hyperlipidemia, cancer and respiratory illness (asthma,
COPD) to those proportions from available data sources
in Switzerland. Data on further chronic conditions
could not be presented, since epidemiological data in
Switzerland are very scarce. We found a high level of
agreement between the estimates using pharmacy data
and those reported by epidemiological studies. Propor-
tions of cancer, cardiovascular diseases, diabetes and re-
spiratory illness matched quite well [25,28,31,34]. For
hyperlipidemia, study results showed lower prevalence
estimates than those revealed in our pharmacy based
study [27,33]. One explanation for the discrepancy be-
tween our findings and those from Pèchere-Bertschi
et al. [27] and Firmann et al. [33] is the questionable
representativeness for the general Swiss population. For
example, Firmann et al. [33] collected data from a sam-
ple of 6′084 subjects living in one Swiss city, Lausanne,
with a relatively high percentage of non-Swiss compared
to other cities. Moreover, this study was conducted six
years ago and recent trends in prevalence are not taken
into account.
There are some limitations addressing the accuracy of
our estimates. About 3% of the used claims invoices
were paid directly by the patients and not by the health
insurer. Drug data may be underrepresented since claims
data are not completely recorded. Furthermore, the
number of prescribed drugs was underreported because
they were obtained exclusively in outpatient settings.
Additionally, drug-based diagnoses are naturally
regarded as a proxy for a medical diagnosis. Since we
excluded ATC-codes which could not be matched to
Table 5 Proportions of chronically ill patients compared to other epidemiological data







design (year of data)
Reference Proportion of
patients (%)
Cancer 1.5 All malignant neoplasms
excluding non-melanoma
skin cancer
Registry data (1992) Micheli et al. 2002 [25] 1.4
1.4 Registry data (2008) WHO 2008 [26]
Cardiovascular diseases






36.0 High blood pressure
Epidemiological data
(2003–2006) Firmann et al. 2008 [28]
34.4 Hypertension
Epidemiological data
(1999-2009) Guessous et al. 2012 [29]
Diabetes mellitus 6.3 Type 2 diabetes
Epidemiological data



















(2003–2006) Firmann et al. 2010 [33]
Respiratory illness
(asthma, COPD) 5.7-10.0 Asthma
Epidemiological data




(2002) Bridevaux et al. 2008 [35]
Proportions of patients with cancer, respiratory illness, cardiovascular diseases and cardiovascular risk factors based on data used in this study (2011) compared to
proportions from available data sources in Switzerland.
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Moreover, we are not able to distinguish specific
chronic diseases such as hypertension from other car-
diovascular diseases. For legal and ethical reasons as
well as regarding data security, data do not include
medical diagnoses and clinical procedures, and thus we
are unable to give more information on chronic condi-
tions as well as to provide prevalence estimates based
on medical diagnoses (e.g. ICD-10) for comparisons in
the same data source. Furthermore, in Switzerland
reliable epidemiological data are scare. Appropriate
additional, independent samples for comparing the
prevalence estimates are not widely available. However,
drug-based diagnoses could not completely substitute,
but add clinical data. Mapping medication classes to
chronic conditions is a frequently recommended and
used in previous studies [10,12,21]. Moreover, we
assume that no patient is prescribed a drug for chronic
conditions such as insulin without a serious indication
of diabetes. However, this study has several strengths.
Our study is based on a very comprehensive administrative
claims database for a large population across Switzerland
with an almost complete recording of prescribed drug data.
Administrative data are a consistently available source ofinformation on morbidity, health care use and costs of care.
They are reliable, longitudinal, practice-based, large in size
and widely accepted in epidemiological, health services
and outcomes research to assess prevalence. Moreover,
studies developing risk models emphasised that pre-
scription data derived from administrative claims data-
base have several advantages over diagnostic data
regarding reliability, timeliness and completeness of
data [7,11,48]. In the Dutch health care system, the use
of information on chronic conditions obtained from
claims for prescribed drugs are well established as a
helpful instrument for improving risk equalisation be-
tween the sickness funds as well as in capitation mod-
elling [19,20,49]. In Switzerland, there is an on-going
debate about the optimal risk equalisation scheme
[50-53]. The present Swiss risk equalisation scheme is
a demographics-based risk equalisation model which
based on age, sex and an at least three successive
night-stays in a hospital or nursing home (in the previ-
ous year) as equalising elements. In 2011, the Swiss
parliament has decided to refine the risk equalisation
by diagnoses based on pharmacy data, since no appro-
priate data on diagnosed diseases exist. Consequently,
it is particularly important to identify those ATC-
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of population’s common diseases. Pharmacy-based,
estimated prevalence data might be a useful addition
for risk adjustment modelling in health care delivery
systems with demographics-based risk equalisation
schemes.
Conclusions
Using pharmacy data, we developed an updated and im-
proved approach for a feasible and efficient measure of
patients’ chronic disease status. Pharmacy drug data may
be a valuable source for measuring population’s burden
of disease, when clinical data are missing. This approach
may contribute to health policy debates about health ser-
vices sources and risk adjustment modelling.
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